A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)
Authors
de Leeuw, A.Giralt, J.
Tao, Y.
Benavente, S.
France Nguyen, T. V.
Hoebers, F. J. P.
Hoeben, A.
Terhaard, C. H. J.
Wai Lee, Lip
Friesland, S.
Steenbakkers, R.
Tans, L.
Heukelom, J.
Kayembe, M. T.
van Kranen, S. R.
Bartelink, H.
Rasch, C. R. N.
Sonke, J. J.
Hamming-Vrieze, O.
Affiliation
Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: This multicenter randomized phase III trial evaluated whether locoregional control of patients with LAHNSCC could be improved by fluorodeoxyglucose-positron emission tomography (FDG-PET)-guided dose-escalation while minimizing the risk of increasing toxicity using a dose-redistribution and scheduled adaptation strategy. MATERIALS AND METHODS: Patients with T3-4-N0-3-M0 LAHNSCC were randomly assigned (1:1) to either receive a dose distribution ranging from 64-84 Gy/35 fractions with adaptation at the 10thfraction (rRT) or conventional 70 Gy/35 fractions (cRT). Both arms received concurrent three-cycle 100 mg/m(2)cisplatin. Primary endpoints were 2-year locoregional control (LRC) and toxicity. Primary analysis was based on the intention-to-treat principle. RESULTS: Due to slow accrual, the study was prematurely closed (at 84 %) after randomizing 221 eligible patients between 2012 and 2019 to receive rRT (N = 109) or cRT (N = 112). The 2-year LRC estimate difference of 81 % (95 %CI 74-89 %) vs. 74 % (66-83 %) in the rRT and cRT arm, respectively, was not found statistically significant (HR 0.75, 95 %CI 0.43-1.31,P=.31). Toxicity prevalence and incidence rates were similar between trial arms, with exception for a significant increased grade ≥ 3 pharyngolaryngeal stenoses incidence rate in the rRT arm (0 versus 4 %,P=.05). In post-hoc subgroup analyses, rRT improved LRC for patients with N0-1 disease (HR 0.21, 95 %CI 0.05-0.93) and oropharyngeal cancer (0.31, 0.10-0.95), regardless of HPV. CONCLUSION: Adaptive and dose redistributed radiotherapy enabled dose-escalation with similar toxicity rates compared to conventional radiotherapy. While FDG-PET-guided dose-escalation did overall not lead to significant tumor control or survival improvements, post-hoc results showed improved locoregional control for patients with N0-1 disease or oropharyngeal cancer treated with rRT.Citation
de Leeuw A, Giralt J, Tao Y, Benavente S, France Nguyen TV, Hoebers FJP, et al. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Jul;196:110281. PubMed PMID: 38636708. Epub 2024/04/19. eng.Journal
Radiotheraphy and OncologyDOI
10.1016/j.radonc.2024.110281PubMed ID
38636708Additional Links
https://dx.doi.org/10.1016/j.radonc.2024.110281Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2024.110281
Scopus Count
Collections
Related articles
- Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer.
- Authors: Gouw ZAR, La Fontaine MD, Vogel WV, van de Kamer JB, Sonke JJ, Al-Mamgani A
- Issue date: 2020 Nov 15
- Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.
- Authors: Rasmussen JH, Håkansson K, Vogelius IR, Aznar MC, Fischer BM, Friborg J, Loft A, Kristensen CA, Bentzen SM, Specht L
- Issue date: 2016 Jul
- Long-term outcome of (18) F-fluorodeoxyglucose-positron emission tomography-guided dose painting for head and neck cancer: Matched case-control study.
- Authors: Berwouts D, Madani I, Duprez F, Olteanu AL, Vercauteren T, Boterberg T, Deron P, Bonte K, Huvenne W, De Neve W, Goethals I
- Issue date: 2017 Nov
- Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
- Authors: Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C
- Issue date: 2013 Feb 22
- Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.
- Authors: van den Bosch S, Dijkema T, Kunze-Busch MC, Terhaard CH, Raaijmakers CP, Doornaert PA, Hoebers FJ, Vergeer MR, Kreike B, Wijers OB, Oyen WJ, Kaanders JH
- Issue date: 2017 Mar 21